Background

Currently, there is no formally accepted pharmacological treatment for COVID-19.

Materials and methods

We included COVID-19 outpatients of a Peruvian primary care center from Lima, Peru, who were treated between April 30 - September 30, 2020, with hydroxychloroquine and azithromycin. Logistic regression was applied to determine factors associated with case-fatality rate.

Results

A total of 1265 COVID-19 patients with an average age of 44.5 years were studied. Women represented 50.1% of patients, with an overall 5.9 symptom days, SpO2 97%, temperature of 37.3 °C, 41% with at least one comorbidity and 96.1% one symptom or sign. No patient treated within the first 72 h of illness died. The factors associated with higher case fatality rate were age (OR = 1.06; 95% CI 1.01–1.11, p = 0.021), SpO2 (OR = 0.87; 95% CI 0.79–0.96, p = 0.005) and treatment onset (OR = 1.16; 95% CI 1.06–1.27, p = 0.002), being the latter the only associated in the multivariate analysis (OR = 1.18; 95% CI 1.05–1.32, p = 0.005). 0.6% of our patients died.

Conclusions

The case fatality rate in COVID-19 outpatients treated with hydroxychloroquine/azithromycin was associated with the number of days of illness on which treatment was started.

中文翻译：

---

COVID-19 中的羟氯喹/阿奇霉素：治疗时间与病死率之间的关联

背景

目前，没有正式接受的 COVID-19 药物治疗。

材料和方法

我们纳入了来自秘鲁利马的秘鲁初级保健中心的 COVID-19 门诊患者，他们在 2020 年 4 月 30 日至 9 月 30 日期间接受了羟氯喹和阿奇霉素治疗。应用逻辑回归来确定与病死率相关的因素。

结果

共研究了 1265 名平均年龄为 44.5 岁的 COVID-19 患者。女性占患者的 50.1%，总体症状天数为 5.9 天，SpO2 为 97%，体温为 37.3 °C，41% 至少有一种合并症，96.1% 有一种症状或体征。发病后 72 小时内接受治疗的患者均未死亡。与较高病死率相关的因素是年龄（OR = 1.06；95% CI 1.01-1.11，p = 0.021）、SpO2（OR = 0.87；95% CI 0.79-0.96，p = 0.005）和治疗开始（OR = 1.16；95% CI 1.06–1.27，p = 0.002），后者是多变量分析中唯一相关的（OR = 1.18；95% CI 1.05–1.32，p = 0.005）。0.6% 的患者死亡。

结论

接受羟氯喹/阿奇霉素治疗的 COVID-19 门诊患者的病死率与开始治疗的患病天数有关。